# Call for Abstracts | National Cannabis Research Conference | Duncan Mackie, Ph.D. > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/national-cannabis-research-conference-call-for-abstracts/ > **Published:** 2026-04-03T02:02:55-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:31:23-04:00 > **Clinical Summary:** Submit your work to the national cannabis research conference. Explore rigorous peer-reviewed cannabis research abstracts and clinical findings. --- ✦ New CED Clinical Relevance  #70Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic ResearchClinical EvidenceMedical EducationCannabis SciencePeer Review Why This Matters Academic conferences drive the translation of research into clinical practice, and [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) desperately needs more rigorous peer-reviewed research. The quality and scope of abstracts accepted will signal whether [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) is maturing toward mainstream medical standards or remaining in preliminary phases. Clinical Summary A call for abstracts represents an opportunity for researchers to present findings at what appears to be a national [cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) conference. Without details on the conference organizers, peer review standards, or focus areas, the clinical significance depends entirely on the academic rigor and institutional backing. Quality research conferences require strict methodological standards and independent peer review to generate actionable clinical insights. Dr. Caplan’s Take “I evaluate cannabis conferences by their commitment to evidence standards, not their enthusiasm for the plant. The real question is whether this will advance rigorous [clinical research](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) or simply provide another platform for preliminary findings.” Clinical Perspective 🧠 Clinicians should look for conferences that emphasize randomized controlled trials, standardized outcome measures, and institutional research backing. Abstract calls from established medical institutions or organizations with clear peer review processes typically yield more clinically relevant findings than industry-sponsored events. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Call%20for%20Abstracts%20%7C%20National%20Cannabis%20Research%20Conference%20%7C%20Duncan%20Mackie%2C%20Ph.D...%20%40drcaplan&url=https%3A//www.linkedin.com/posts/duncan-mackie-phd_call-for-abstracts-national-cannabis-research-activity-7445557007329239041-JMvb)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//www.linkedin.com/posts/duncan-mackie-phd_call-for-abstracts-national-cannabis-research-activity-7445557007329239041-JMvb)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Call%20for%20Abstracts%20%7C%20National%20Cannabis%20Research%20Conference%20%7C%20Duncan%20Mackie%2C%20Ph.D...%20--%20via%20%40drcaplan.bsky.social%20https%3A//www.linkedin.com/posts/duncan-mackie-phd_call-for-abstracts-national-cannabis-research-activity-7445557007329239041-JMvb)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://www.linkedin.com/posts/duncan-mackie-phd_call-for-abstracts-national-cannabis-research-activity-7445557007329239041-JMvb](https://www.linkedin.com/posts/duncan-mackie-phd_call-for-abstracts-national-cannabis-research-activity-7445557007329239041-JMvb) Table of Contents - [FAQ](#FAQ)[What is the clinical relevance rating of this cannabis research?](#What_is_the_clinical_relevance_rating_of_this_cannabis_research) - [What type of cannabis-related content does this article cover?](#What_type_of_cannabis-related_content_does_this_article_cover) - [Who should pay attention to this cannabis research?](#Who_should_pay_attention_to_this_cannabis_research) - [Is this information considered established medical practice?](#Is_this_information_considered_established_medical_practice) - [Where does this cannabis research information come from?](#Where_does_this_cannabis_research_information_come_from) - [Related](#Related) ## FAQ #### What is the clinical relevance rating of this cannabis research? This article has been assigned CED Clinical Relevance #70, indicating “Notable Clinical Interest.” This rating signifies emerging findings or policy developments that are worth monitoring closely by healthcare professionals. #### What type of cannabis-related content does this article cover? This article covers multiple aspects of cannabis science including research findings, clinical evidence, medical education, and cannabis science. It appears to be part of CED Clinic’s cannabis news coverage focusing on clinical applications. #### Who should pay attention to this cannabis research? Healthcare professionals, medical educators, and clinicians working with cannabis therapeutics should monitor this content. The “Notable Clinical Interest” rating suggests it contains information relevant to clinical practice and [patient care](https://cedclinic.com/cannabis-cardiovascular-risk-impact/). #### Is this information considered established medical practice? No, this appears to be emerging research or policy developments rather than established practice. The classification as “emerging findings” suggests this information is still developing and requires close monitoring rather than immediate clinical implementation. #### Where does this cannabis research information come from? This content is published by CED Clinic as part of their cannabis news coverage. It represents curated information focused on clinical relevance and medical education in the cannabis therapeutics field. {“@context”: “https://schema.org”, “@type”: “NewsArticle”, “headline”: “Call for Abstracts | National Cannabis Research Conference | Duncan Mackie, Ph.D.”, “url”: “https://www.linkedin.com/posts/duncan-mackie-phd_call-for-abstracts-national-cannabis-research-activity-7445557007329239041-JMvb”, “datePublished”: “2026-04-02T21:55:27Z”, “about”: “call abstracts national cannabis research conference”} [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [New research suggests cannabinoids like CBD and CBG may help improve fatty liver disease.](https://cedclinic.com/cannabinoids-fatty-liver-clinical-relevance/) Explore emerging clinical evidence on cannabinoids and their potential benefits for [fatty liver disease](https://cedclinic.com/cannabinoid-receptor-type-1-antagonist-obesity-steatohepatitis/) management. [Read More](https://cedclinic.com/cannabinoids-fatty-liver-clinical-relevance/) [Medicinal cannabis export licenses take 6.4 working days in 2026 – New Zealand Doctor](https://cedclinic.com/medicinal-cannabis-export-licensing-process-2026/) Understand the regulatory landscape and timelines for medicinal cannabis export licensing in 2026. [Learn More](https://cedclinic.com/medicinal-cannabis-export-licensing-process-2026/) [Cbd Gummy Bears Without Thc! What Are Terpenes Pamphlet! Quality Of CBD Source:](https://cedclinic.com/cbd-product-quality-clinical-evidence/) Discover the role of terpenes and quality considerations in THC-free CBD gummy bears. [Explore Now](https://cedclinic.com/cbd-product-quality-clinical-evidence/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).